Menu
home
about us
Investment Approach
Client Service Approach
Market Analysis Summary
Mission Statement
Value Proposition
Team Biographies
Firm ADV PDFs
Form CRS
Firm Brochure-Part 2A of Form ADV
Brochure Supplement Amit Stavinsky
Brochure Supplement Frank Parks
Brochure Supplement Dominick Savo
Brochure Supplement Richard Mason
Brochure Supplement Joe Estes
Brochure Supplement Jonathan Ezra
Statement Of Financial Strength
Job Opportunities
Tamar Advisors
Own Your Practice
Letter to Clients
member log-in
contact us
PRODUCTS
Fixed Income Portfolio (FIP)
FIP Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Market (TAM)
TAM sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Market Value Securities (MVS)
MVS Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Value (TAV)
TAV Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Municipal Bonds
Taxable Bonds
Par, Premium, and Discount Bonds
Rating and Analyzing Bonds
Refunding & Pre-refunding
Bond Yields
Yield Curve
Secured Bonds
Mortgage Bonds
Unsecured Bonds
Debentures
Subordinated Debentures
Zero-Coupon Bonds
Convertible Bonds
High Yield Dividend Stocks
Independent Money Managers
Fees & Compensation
Corporate Cash Management
Fees & Compensation
Estate Planning
Financial Planning
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
Professional Alliance Network
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
MUNICIPAL BONDS
Municipal Bond Presentation
About Us
The Management
Global Asset Allocation Products
FIP Program
Classifying Municipal Bonds
Revenue Bonds
Credit Factors Affecting General Obligation Bonds
Credit Factors Affecting the Quality of Local Municipal Bonds
Analyzing the Credit Quality of General Obligation Bonds
Analyzing the Credit Quality of Revenue Municipal Bonds
What We Buy Currently
What We Normally Don’t Buy
Municipal Bonds – Unique Asset Class
Default Rates
Yield Difference
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same-Day Allocation
TSL’s Turnkey Operation Platform
Sample Portfolio
Sample Portfolio Analysis
Classifying Municipal Bonds
Revenue Municipal Bonds
Types of Revenue Municipal Bonds
Industrial Development Revenue Bonds
Lease-back Bonds
Special Tax Bonds
NHA/PHA Bonds
Moral Obligation Bonds
Municipal Notes
TANs/RANs
BANs
CLNs/GANs
Variable Rate Bonds/Notes
Build America Bonds
Double-Barreled Bonds
Bond Index Components
Open-end-Closed-end-Indenture
Sinking Fund
Bond Contracts
Bond Indenture
Official Statement
Bond Issuance Process
Analyzing GO Bonds
Analyzing Revenue Bonds
Debt Ratios
General Price Analysis of Municipal Bonds
Liquidity
Interest Rate Risk
Credit Risk
Coupon Risk
Maturity Risk
Municipal Bond Insurance
Municipal Bonds Unique Asset Class
Default Rates
What We Buy Currently
What We Normally Don’t Buy
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same Day Allocation
Traditional Broker/Dealer Execution Flow
TSL's Turnkey Operation Platform
INDEX FUNDS
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Account Requirements
Client Information
Client Contact with Portfolio Manager(s)
Additional Information
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
EVENTS
FIP
Event Schedule
Municipal Bond Presentation
TAM
Event Schedule
Total Asset Market (TAM sm) Presentation
TAF
Event Schedule
Total Asset Fund (TAF sm) Presentation
MVS
Event Schedule
Market Value Securities (MVS sm) Presentation
Featured Event
Calendar of Events
Events History
Investing During Uncertain Times
Read FULL Seminar Here
Tax-Free Income Seminar
Bond Fund Seminar
RSVP-Signup Form
MARKET RESEARCH
Featured Quarterly Newsletter
Featured Articles
Contrarian Notes Blog
home
about us
Investment Approach
Client Service Approach
Market Analysis Summary
Mission Statement
Value Proposition
Team Biographies
Firm ADV PDFs
Form CRS
Firm Brochure-Part 2A of Form ADV
Brochure Supplement Amit Stavinsky
Brochure Supplement Frank Parks
Brochure Supplement Dominick Savo
Brochure Supplement Richard Mason
Brochure Supplement Joe Estes
Brochure Supplement Jonathan Ezra
Statement Of Financial Strength
Job Opportunities
Tamar Advisors
Own Your Practice
Letter to Clients
member log-in
contact us
PRODUCTS
Fixed Income Portfolio (FIP)
FIP Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Market (TAM)
TAM sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Market Value Securities (MVS)
MVS Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Value (TAV)
TAV Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Municipal Bonds
Taxable Bonds
Par, Premium, and Discount Bonds
Rating and Analyzing Bonds
Refunding & Pre-refunding
Bond Yields
Yield Curve
Secured Bonds
Mortgage Bonds
Unsecured Bonds
Debentures
Subordinated Debentures
Zero-Coupon Bonds
Convertible Bonds
High Yield Dividend Stocks
Independent Money Managers
Fees & Compensation
Corporate Cash Management
Fees & Compensation
Estate Planning
Financial Planning
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
Professional Alliance Network
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
MUNICIPAL BONDS
Municipal Bond Presentation
About Us
The Management
Global Asset Allocation Products
FIP Program
Classifying Municipal Bonds
Revenue Bonds
Credit Factors Affecting General Obligation Bonds
Credit Factors Affecting the Quality of Local Municipal Bonds
Analyzing the Credit Quality of General Obligation Bonds
Analyzing the Credit Quality of Revenue Municipal Bonds
What We Normally Buy
What We Normally Don’t Buy
Municipal Bonds – Unique Asset Class
Default Rates
Yield Difference
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same-Day Allocation
TSL’s Turnkey Operation Platform
Classifying Municipal Bonds
Revenue Municipal Bonds
Types of Revenue Municipal Bonds
Industrial Development Revenue Bonds
Lease-back Bonds
Special Tax Bonds
NHA/PHA Bonds
Moral Obligation Bonds
Municipal Notes
TANs/RANs
BANs
CLNs/GANs
Variable Rate Bonds/Notes
Build America Bonds
Double-Barreled Bonds
Bond Index Components
Open-end-Closed-end-Indenture
Sinking Fund
Bond Contracts
Bond Indenture
Official Statement
Bond Issuance Process
Analyzing GO Bonds
Analyzing Revenue Bonds
Debt Ratios
General Price Analysis of Municipal Bonds
Liquidity
Interest Rate Risk
Credit Risk
Coupon Risk
Maturity Risk
Municipal Bond Insurance
Municipal Bonds Unique Asset Class
Default Rates
What We Buy Currently
What We Normally Don’t Buy
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same Day Allocation
Traditional Broker/Dealer Execution Flow
TSL's Turnkey Operation Platform
INDEX FUNDS
Total Asset Fund (TAF)
TAF® Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Additional Information
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
EVENTS
FIP
Event Schedule
TAM
Event Schedule
Total Asset Market (TAM sm) Presentation
TAF
Event Schedule
Total Asset Fund (TAF sm) Presentation
MVS
Event Schedule
Market Value Securities (MVS sm) Presentation
Featured Event
Calendar of Events
Events History
Investing During Uncertain Times
Read FULL Seminar Here
Tax-Free Income Seminar
Bond Fund Seminar
RSVP-Signup Form
MARKET RESEARCH
Featured Quarterly Newsletter
Featured Articles
Contrarian Notes Blog
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude+Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Articles published by FSD Pharma Inc.
< Previous
1
2
Next >
FSD Pharma Participating in H.C. Wainwright 24th Annual Global Investment Conference, On-Demand Presentation Available
September 12, 2022
From
FSD Pharma Inc.
Via
Business Wire
Tickers
CSE:HUGE
HUGE
FDA and Health Canada Clear IND for FSD Pharma to Proceed with Phase 2 Trial of FSD201 for Nociplastic Pain Associated with Idiopathic Mast Cell Activation Syndrome
September 06, 2022
From
FSD Pharma Inc.
Via
Business Wire
Tickers
CSE:HUGE
HUGE
FSD Pharma Subsidiary Lucid Psycheceuticals Files for Patent On Novel Formulations of Palmitoylethanolamide, Presents Preclinical Toxicology Results at an International Symposium
July 13, 2022
From
FSD Pharma Inc.
Via
Business Wire
Tickers
CSE:HUGE
HUGE
FSD Pharma Inc. Announces Results of Annual General Meeting of Shareholders And Other Corporate Updates
June 27, 2022
From
FSD Pharma Inc.
Via
Business Wire
Tickers
CSE:HUGE
HUGE
FSD Pharma Files Investigational New Drug Application (“IND”) with FDA and Health Canada for Phase-2 Trial of FSD-201 for an Inflammatory disorder and Provides Corporate Updates
May 31, 2022
From
FSD Pharma Inc.
Via
Business Wire
Tickers
CSE:HUGE
HUGE
FSD Pharma Issues Circular, Adopts Incentive Plan and Grants PSUs
May 24, 2022
From
FSD Pharma Inc.
Via
Business Wire
Tickers
CSE:HUGE
HUGE
FSD Pharma Closes CAD$16.4 Million Sale of Non-Core Assets
May 10, 2022
From
FSD Pharma Inc.
Via
Business Wire
Tickers
CSE:HUGE
HUGE
FSD Pharma Announces Dismissal of Derivative Complaint
May 06, 2022
From
FSD Pharma Inc.
Via
Business Wire
Tickers
CSE:HUGE
HUGE
FSD Pharma Announces Engagement with Tekkfund Capital and Share Issuance to Crystal Research Associates
May 02, 2022
From
FSD Pharma Inc.
Via
Business Wire
Tickers
CSE:HUGE
HUGE
FSD Pharma Appoints Julia Levy Award Recipient David Allan and Dr. John McGraw to Advisory Board
April 21, 2022
From
FSD Pharma Inc.
Via
Business Wire
Tickers
CSE:HUGE
HUGE
FSD Pharma Announces Cancellation of Certain Shares Issued to Former Chief Executive Officer Dr. Raza Bokhari
April 08, 2022
From
FSD Pharma Inc.
Via
Business Wire
Tickers
CSE:HUGE
HUGE
FSD Pharma Issues Corporate Updates
April 06, 2022
From
FSD Pharma Inc.
Via
Business Wire
Tickers
CSE:HUGE
HUGE
FSD Pharma Announces Filing of Year-End 2021 Results
March 31, 2022
From
FSD Pharma Inc.
Via
Business Wire
Tickers
CSE:HUGE
HUGE
FSD Pharma Announces Executive Informational Overview Report Produced by Crystal Research Associates LLC
March 15, 2022
From
FSD Pharma Inc.
Via
Business Wire
Tickers
CSE:HUGE
HUGE
FSD Pharma Announces Agreement for Sale of Cobourg Facility for CAD$16,500,000
February 25, 2022
From
FSD Pharma Inc.
Via
Business Wire
Tickers
CSE:HUGE
HUGE
FSD Pharma Announces Launch of New Corporate Website
January 20, 2022
From
FSD Pharma Inc.
Via
Business Wire
Tickers
CSE:HUGE
HUGE
FSD Pharma Congratulates Dr. Eleanor Fish on Being Named to the Order of Canada
January 18, 2022
From
FSD Pharma Inc.
Via
Business Wire
Tickers
CSE:HUGE
HUGE
FSD Pharma to Present at the H.C. Wainwright Bioconnect Conference on January 10-13th
January 04, 2022
From
FSD Pharma Inc.
Via
Business Wire
Tickers
CSE:HUGE
HUGE
FSD Pharma Announces Share Repurchase Program
December 30, 2021
From
FSD Pharma Inc.
Via
Business Wire
Tickers
CSE:HUGE
HUGE
FSD Pharma Establishes New Regulatory Advisory Board with the Appointment of Joga Gobburu, Ph.D., and Mary Melnyk, Ph.D., as Members
December 09, 2021
From
FSD Pharma Inc.
Via
Business Wire
Tickers
CSE:HUGE
HUGE
FSD Pharma to Present at the H.C. Wainwright 2nd Annual Psychedelics Virtual Conference on December 6th
December 03, 2021
From
FSD Pharma Inc.
Via
Business Wire
Tickers
CSE:HUGE
HUGE
FSD Pharma Unveils Videos Demonstrating Positive Effects of Lucid-MS in Treating Multiple Sclerosis in Pre-Clinical Models (Mouse Models)
December 02, 2021
From
FSD Pharma Inc.
Via
Business Wire
Tickers
CSE:HUGE
HUGE
FSD Pharma Expands Research and Clinical Advisory Board with Appointment of World-Renowned Immunologist and Cytokine Expert Dr. Eleanor N. Fish
November 16, 2021
From
FSD Pharma Inc.
Via
Business Wire
Tickers
CSE:HUGE
HUGE
FSD Pharma Signs Agreement with Covar Pharmaceuticals to Support the Development of Lucid-PSYCH
October 19, 2021
From
FSD Pharma Inc.
Via
Business Wire
Tickers
CSE:HUGE
HUGE
FSD Pharma Announces Engagement with Capital Markets Communications Providers and Market Maker
September 22, 2021
From
FSD Pharma Inc.
Via
Business Wire
Tickers
CSE:HUGE
HUGE
FSD Pharma Announces Closing of Lucid Psycheceuticals Acquisition
September 21, 2021
From
FSD Pharma Inc.
Via
Business Wire
Tickers
CSE:HUGE
HUGE
FSD Pharma Announces Definitive Agreement to Acquire Lucid Psycheceuticals
August 25, 2021
From
FSD Pharma Inc.
Via
Business Wire
Tickers
CSE:HUGE
HUGE
FSD Pharma Inc. Announces Termination of FSD-201 Phase 2 Clinical Trial
August 24, 2021
From
FSD Pharma Inc.
Via
Business Wire
Tickers
CSE:HUGE
HUGE
FSD Pharma Inc. Announces Termination of Chief Executive Officer Dr. Raza Bokhari for Cause
July 27, 2021
From
FSD Pharma Inc.
Via
Business Wire
Tickers
CSE:HUGE
HUGE
FSD Pharma Inc. Appoints a New Independent Director
June 03, 2021
From
FSD Pharma Inc.
Via
Business Wire
Tickers
CSE:HUGE
HUGE
< Previous
1
2
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.